P10

P10 is a synthetic 13-amino acid peptide that acts as a potent dual antagonist of the C-X-C chemokine receptor type 4 (CXCR4) and the formyl peptide receptor 1 (FPR1). Developed by the Fondazione Ricerca Traslazionale (FoRT), the peptide is derived from the sequence of the urokinase-type plasminogen activator receptor (uPAR) and is engineered with D-alanine residues at both the N- and C-termini, along with a cyclohexylalanine (Cha) residue, to enhance its stability against proteolytic degradation. P10 specifically disrupts the CXCR4/CXCL12 and uPAR/FPR1 signaling axes, which are frequently upregulated in various malignancies, including non-small cell lung cancer (NSCLC), and are associated with tumor progression, epithelial-mesenchymal transition (EMT), and metastasis. By competitively inhibiting these receptors, P10 suppresses downstream signaling pathways such as MAPK/ERK and PI3K/Akt, leading to reduced tumor cell migration, invasion, and proliferation. Preclinical studies have demonstrated its potential to inhibit tumor growth and metastatic spread in NSCLC models, both as a monotherapy and in combination with other targeted agents.

Other names

d-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-d-AlaCXCR4 antagonist P10CXCR-4 antagonist P10CXCR 4 antagonist P10uPAR-derived peptide P10peptide 10peptide10peptide-10